In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Prognostic implications of cardiac magnetic resonance in patient with mid range ejection fraction: can we predict worse outcomes?

Session Poster Session 6

Speaker Marina Pascual Izco

Event : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance
  • Session type : Poster Session

Authors : A Lorente Ros (Madrid,ES), M Pascual Izco (Madrid,ES), M Flores (Toledo,ES), R Hinojar Baydes (Madrid,ES), GL Alonso Salinas (Madrid,ES), MA Fernandez Mendez (Madrid,ES), M Plaza Martin (Madrid,ES), A Garcia De Vicente (Madrid,ES), S Del Prado Diaz (Madrid,ES), M Abellas Sequeiros (Madrid,ES), A Garcia Martin (Madrid,ES), A Gonzalez Gomez (Madrid,ES), JL Zamorano Gomez (Madrid,ES), C Fernandez-Golfin Loban (Madrid,ES)

A Lorente Ros1 , M Pascual Izco1 , M Flores2 , R Hinojar Baydes1 , GL Alonso Salinas1 , MA Fernandez Mendez1 , M Plaza Martin1 , A Garcia De Vicente1 , S Del Prado Diaz1 , M Abellas Sequeiros1 , A Garcia Martin1 , A Gonzalez Gomez1 , JL Zamorano Gomez1 , C Fernandez-Golfin Loban1 , 1University Hospital Ramon y Cajal de Madrid, Cardiology Department - Madrid - Spain , 2Hospital Virgen de la Salud, Cardiology - Toledo - Spain ,


Purpose. According to current ESC guidelines, mid-range ejection fraction (mrEF) might represent a separate subgroup of patients with distinct underlying characteristics, prognosis and treatment response. Cardiac magnetic resonance (CMR) is the gold standard for measuring volumes, mass and ejection fraction of the heart. We aimed to find long-term prognostic value of various CMR parameters in patients mrEF.

Methods. 137 patients with mrEF underwent CMR (1.5T) between 2012 and 2018 and were consecutively included. Volumes, mass and ejection fraction were assessed using short axis SSFP images and the Simpson method (using commercially available software). Myocardial fibrosis was determined by late gadolinium enhancement (LGE). Clinical parameters after a median of 762 (230-1315 days) were recorded. Patients with other significant cardiac affection rather than mrEF were excluded (pre-capillary pulmonary hypertension and significant valve disease). The primary endpoint was defined as a combined outcome of all-cause death or heart failure decompensation requiring in-hospital admission.

Results. Mean age was 63.0 ±12.4 years. 76.6% were males.  Mean left ventricle ejection fraction (LVEF) was 45±2.69 %. Main aetiologies were ischemic (46%), idiopathic (32.12%), myocarditis (9.5%), tachycardiomyopathy (6.57 %) enolic (2.2%) stress cardiomyopathy (0.7%) and others (2.9%).

A combined model for predicting outcomes in patients with mrEF using CMR parameters was obtained. This model was able to predict 32.7% (coefficient of determination, R-squared) of the adverse events (p<0.01). Significant CMR parameters and results are shown on table 1.

Conclusions. In patients with mid-range ejection fraction, RV volumes and ejection fraction, as well as LV mass and LA volume, were significant predictors of worse outcomes in a combined model. If supported by further studies, these findings may help the clinician select the patients with higher risk of complications and in need of a closer follow-up.


p value

iRVEDV (indexed right ventricular end-diastolic volume)


RVEF (right ventricle ejection fraction


iRVESV(indexed right ventricular end-systolic volume)


Presence of late enhancement (yes/no)


iLA (indexed left atrial) Volume


iLV (indexed left ventricle) mass


Combined model for predicting outcomes in patients with mrEF using CMR parameters. Variables and their significance are shown individually.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are